Mitral valve-in-valve implantation during pregnancy

A 32-year-old, 11-week pregnant African woman with known rheumatic heart disease presented to the emergency department with worsening shortness of breath on exertion. She had undergone a double bioprosthetic valve replacement and left atrial appendage resection 8 years prior for severe mitral stenosis, moderate mitral regurgitation and moderate aortic regurgitation. A transo-oesophageal echocardiography at this presentation confirmed a morphologically calcified and stenosed mitral bioprosthesis, with moderate stenosis of her aortic bioprosthesis. Her multidisciplinary team, including cardiologists, cardiothoracic surgeons and obstetricians, came to a consensus decision to proceed with a transseptal transcatheter valve implantation within the mitral valve prosthesis (valve-in-valve implantation). Transthoracic echocardiography performed 2 months post procedure showed satisfactory mitral valve gradients and at 30 weeks’ gestation, she successfully delivered her fifth child. 2 years later, the valve in valve complex is still functioning well.

Redo Aortic and Mitral Valve Replacement using St. Jude Medical Mechanical Prosthesis in a Patient with Degenerated Mitral Bioprosthesis and Severe Aortic Regurgitation: A Video Presentation

The American College of Cardiology/American Heart Association practice guidelines suggest bioprosthetic aortic and mitral valve replacement is a reasonable option for patients older than 65 years and for selected patients younger than 65 years according to patients’ preference. However, routine use of bioprosthetic valves in younger patients remains controversial. Patients prevalence to avoid anticoagulation, decreasing operative risks for valve reoperations, and the availability of catheter valve-in-valve techniques have created a need to reexamine bioprosthetic valve durability, particularly in young patients undergoing valve replacements

First mitral valve replacement using Edwards MITRIS RESILIA mitral valve in a patient with functional mitral regurgitation: a case report

RESILIA tissue expected to prevent structural valve deterioration owing to calcification on leaflets was firstly mounted in a mitral bioprosthesis, named MITRIS RESILIA mitral valve (MITRIS). MITRIS has softer cuff than Magna Mitral Ease and stent posts that deflect to prevent suture looping. A 77-year-old man, having a history of long-standing atrial fibrillation, presented with dyspnea on effort. An echocardiography suggested atrial functional MR. We successfully replaced mitral valve using a 27-mm MITRIS, and his postoperative course was uneventful with good hemodynamics. MITRIS may have advantages for implantability and durability, making it a promising prosthesis for patients requiring mitral surgery.

Transseptal mitral valve-in-valve implantation in a degenerated mitral bioprosthesis: a case report and literature review

We present hereby the case of a 75-year-old woman with a degenerated mitral bioprosthesis and severely reduced left ventricular ejection fraction who underwent a successful trans-septal mitral valve-in-valve (TMViV) replacement using a 29mm Edwards Sapien S3 transcatheter heart valve. We also performed a literature review.